Using Flavonoids to Kill Hepatitis B Virus

Not Applicable

Completed

• Conditions: Hepatitis B Virus Infection
• Interventions: Drug: Flavonoid; Drug: Tenofovir

• Registration Number: NCT07084948
• Lead Sponsor: Trieu, Nguyen Thi, M.D.

Brief Summary

The composition treats Acute Hepatitis, Chronic Hepatitis, Cirrhosis, and hepatocellular carcinoma (S.B.Flavonoids) at an early stage. The product is ascorbic acid, L-Arginine hydrochloride, Kaempferol, Urinariaflavone, 5,6-dihydroxy-7,8,4'-trimethoxy-flavone, Quercetin, and Rutin.

These components have participated in protecting liver cell membranes, focusing on reducing liver stress and supporting their structure, repairing and regenerating new liver parenchyma, preventing fibrosis cell generation, and preventing liver cancer cell growth at an early stage. The composition supplements precursors that help the body strengthen antibodies and reduce the risk of inflammation, and restore the physiological and biochemical functions of liver cells after chronic inflammation.

Detailed Description

The product is Acid ascorbic, L-Arginine hydrochloride, Kaempferol, Urinariaflavone, 5,6-dihydroxy-7,8,4'-trimethoxy-flavone, Quercetin, Rutin as the key compounds in the regeneration of to protect liver cell membranes, focus on reducing liver stress and supporting their prevent structure, fibrosis liver cell fibrosis, removing scar tissue, stimulate and release growth hormones, prevent progression to HCC, and prevent HCC recurrence.

The pharmaceutical ingredients involved in the composition are calculated to increase their effectiveness in preventing and curing acute hepatitis, chronic hepatitis, cirrhosis, and hepatocellular carcinoma.

Currently, many preparations have been and are being studied to fight against acute hepatitis, chronic hepatitis, cirrhosis, and liver cancer globally. The effectiveness of this preparation is a new finding that has been proven over 8 years of follow-up.

This ingredient is used as a supplement to stabilize the endothelium, regulate the amount of cortisol within normal limits, and help the body produce B lymphocytes with a good response.

Acid ascorbic, L-Arginine hydrochloride, Kaempferol, Urinariaflavone, 5,6-dihydroxy-7,8,4'-trimethoxy-flavone, Quercetin, Rutin. Flavonoids participate in cell protection against toxic proteins, which are produced during prolonged inflammation, blocking the action and removing denatured proteins that change the parenchyma of liver cells. The selected flavonoids repaired the fibrotic structure of liver parenchyma after chronic inflammation. Ascorbic acid and L-arginine help to facilitate biological functions in cell adhesion, synergize with flavonoids in cell membrane protection, structural repair, and liver cell regeneration.

Study Timeline

• Study Start: 2015-11-30
• Primary Completion: 2021-10-10
• Study Completion: 2025-06-20
• Study First Submitted: 2025-07-03
• Study First Submitted QC: 2025-07-16
• Study First Posted: 2025-07-25
• Status Verified: 2025-09
• Last Update Submitted: 2025-09-04
• Last Update Posted: 2025-09-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 134

Inclusion Criteria

• All patients with underlying medical conditions who have been taking medications for these conditions.
• Patients with AIDS, HIV, HBV, HCV, and patients with co-infections.
• The cancer patients are stable.
• Patients with congenital or acquired immunodeficiency.

Exclusion Criteria

• Unstable cancer patients.
• Decompensated cirrhosis.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Tenofovir 300mg + SB Flavon	Flavonoid	Experimental benefits in resistance to the Hepatitis B Virus were observed in all patients who had previously received certain components of the treatment for acute hepatitis, chronic hepatitis, cirrhosis, and hepatocellular carcinoma to Tenofovir + SB Flavon for various therapeutic purposes.
Tenofovir 300mg + SB Flavon	Tenofovir	Experimental benefits in resistance to the Hepatitis B Virus were observed in all patients who had previously received certain components of the treatment for acute hepatitis, chronic hepatitis, cirrhosis, and hepatocellular carcinoma to Tenofovir + SB Flavon for various therapeutic purposes.
Tenofovir 300mg	Tenofovir	Experimental benefits in resistance to the Hepatitis B Virus were observed in all patients who received the treatment with only Tenofovir for various therapeutic purposes.

Primary Outcome Measures

Name	Time	Method
Quantification of HBV-DNA, SGPT, SGOT. The test uses sound waves to measure the stiffness of liver tissue on patient cirrhosis	36 months	HBV injure healthy liver cells, causing cell death and inflammation. Healthy liver tissue is replaced with scar tissue and the liver is damaged.

Secondary Outcome Measures

Name	Time	Method
The test uses sound waves to measure the stiffness of liver tissue on patient cirrhosis/Hcc (Arm 2)	36 months	Quantification of HBV-DNA, SGPT, SGOT. The test uses sound waves to measure the stiffness of liver tissue on patient cirrhosis carcinoma occurs most often in people with chronic liver diseases, cirrhosis, such as cirrhosis caused by hepatitis B.

Trial Locations

Locations (2)

Saigon Biopharma LLC; 🇺🇸 Wilmington, Delaware, United States

Saigon Biopharma Company Limited; 🇻🇳 Hồ Chí Minh, Ho Chi Minh City, Vietnam